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In order to determine whether auto antibodies were restricted to some subtypes of epilepsy, we included 81 unselected epileptic
patients and 81 controls, studied clinical data, EEG, neuroimaging, measured antinuclear (ANA), anticardiolipin (aCL) and
2GP1 antibodies.
Results: Epilepsy was active in 74 patients, generalised in 78 and partial in 9. Auto antibodies were positive at the same frequency
and the same level among patients and controls (ANA+ 17% vs. 11%; aCL+ 4% vs. 7%; 2GP1 antibodies+ 5% vs. 6%).
There was no increased frequency of auto antibodies among subgroups of epileptic patients except ANA which were more
frequent when patients had more than 10 seizures per year.
Conclusions: Positivity of ANA, aCL and 2GP1 antibodies is not increased in all types of epilepsy and further studies are
needed to determine exactly which kind of seizure is immune-mediated.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
The clinical features of central nervous system in-
volvement of systemic lupus erythematosus (SLE) and
antiphospholipid syndrome (APS) include epilepsy1, 2
and epilepsy is one of the diagnosis criteria of SLE3.
Epilepsy in SLE could be associated with a higher
titer of antiphospholipid antibodies (APA)4–6. An
association between antinuclear (ANA), anticardi-
olipin antibodies (aCL) and epilepsy, even in patients
without SLE or APS has been postulated7–11. Some
studies pointed out that the presence of auto anti-
bodies could be restricted to partial or uncontrolled
epilepsy8, 9, suggesting the existence of different
subtypes of epileptic syndromes with different abnor-
malities of the immune system. We conducted this
prospective study in order to clarify the relationship
between epilepsy, auto antibodies and anticonvulsants
in unselected epileptic adults.
PATIENTS AND METHODS
Patients
Eighty-one epileptic patients over 15 years old and
81 controls from the internal department of the
‘Percy’ Military Hospital and from the ‘Jean Julliard’
Military Blood Center (Clamart, France) were in-
cluded from June 1997 to June 1999. Blood samples
were obtained after informed consent. Controls were
matched for sex and age and should be taking no
drugs. For each patient, the latest neuroimaging, elec-
troencephalographic studies and clinical records were
prospectively studied before having knowledge of
laboratory results. Patients and controls were screened
for signs of SLE, APS or other autoimmune disor-
ders. Epilepsy was categorised according to the In-
ternational Classification of Epilepsies and Epileptic
Syndromes12.
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Table 1: Characteristics of patients’ aCL, ANA and 2GP1 antibodies.
ANA+ P ACL+ P 2GP1+ P
Patients 3/81 RR = 0.5 14/80 RR = 1.56 4/76 RR = 0.8
Controls 6/81 0.32 9/80 0.29 5/76 0.92
Male 1/54 0.53 9/53 0.89 3/50 0.8
Female 2/27 5/27 1/26
Antiepileptic drugs+ 1/27 0.53 4/27 0.89 1/25 0.84
Antiepileptic drugs− 2/54 10/53 3/51
Implicated drugs in SLE+ 1/31 0.67 4/31 0.39 1/30 0.93
Implicated drugs in SLE− 2/50 10/49 3/46
Generalised epilepsy 3/68 0.98 13/67 0.54 4/63 0.80
Non-generalised epilepsy 0/13 1/13 0/13
Symptomatic epilepsy 1/42 0.95 7/41 0.92 4/40 0.15
Non-symptomatic epilepsy 2/39 7/39 0/36
Active epilepsy 3/74 0.61 14/73 0.45 4/70 0.73
Epilepsy in remission 0/7 0/7 0/6
Epilepsy ≤1 year 2/39 0.95 8/39 0.49 2/37 0.65
Epilepsy ≤5 years 3/56 0.89 10/56 0.85 3/53 0.75
Epilepsy ≤10 years 3/63 0.81 11/62 0.82 4/59 0.63
≤5 seizures/year 0/54 0.06 11/57 0.73 3/54 0.75
≤10 seizures/year 0/63 0.01 13/65 0.65 4/62 0.69
Methods
ANA (positive >160), aCL (positive >15 U/ml) and
anti 2GP1 antibodies (positive >12 U/ml) were de-
tected by immunofluorescence in Hep-2 cells and by
ELISA assay. Blood count and Partial Prothrombin
Time (PPT), Venereal Disease Research Laboratory
(VDRL) and lupus anticoagulant (LA) were per-
formed in all epileptic patients.
STATISTICAL ANALYSIS
With an estimated prevalence of ANA and aCL anti-
bodies in the general population (5, 4%) and among
epileptic patients (25, 20%)7–9, 13, 14, we calculated
that 80 patients were needed in each group to detect
such a difference with 90% certainty and a 5% signif-
icance level15. We estimated the Odds Ratio (OR) us-
ing the Mac Nemar test with one degree of freedom15.
All reported P-values were two-sided.
RESULTS
Median age was 33 years. Seventy-four patients
had active epilepsy and 42 symptomatic seizures.
Generalised epilepsy occurred in 68 patients, par-
tial epilepsy in 9 patients and multiple seizure in
4 patients. Forty-two patients had symptomatic
seizure and 39 patients had epilepsy of unknown
causes. Twenty-seven epileptic patients were taking
antiepileptic drugs and 31 patients a treatment impli-
cated in SLE. No patient had features suggestive of
SLE, APS or autoimmune disease.
Auto antibodies were detected at the same frequency
and the same level in epileptic patients compared
with controls, in epileptic patients treated either with
antiepileptic medication or with implicated drugs in
SLE and in different subtypes of seizure (Table 1).
ANA tended to be more frequent when patients had
more than 10 seizures per year.
LA was positive in one patient (aCL+) and VDRL in
one patient who had no other immunologic abnormal-
ity. Hemoglobin was under 110 g/l in 2 patients, none
of them having auto antibodies. Platelet count was un-
der 100 g/l in 5 patients (2 patients with a chronic un-
explained thrombopenia aCL+, 3 patients with portal
hypertension). PPT was above the normal range by
at least 8 seconds in 3 patients (warfarin = 1, liver
disease = 2).
DISCUSSION
Our data are in agreement with two surveys that
strongly suggest that among epileptic patients, there
were no consistent associations between auto an-
tibodies and specific antiepileptic medications7, 8.
Although we did not find any association between
the prevalence of auto antibodies and epilepsy, it is
relatively certain that there is a relationship between
auto antibodies and epilepsy even in patients without
SLE. In adults, IgG and IgM aCL antibodies were
detected respectively in 31 and 68 of the 163 and 152
epileptic patients versus only in 3 and 6 of the 100
and 83 controls7, 8. Twenty-five and eighteen percent
of these 163 and 152 epileptic patients versus 10 and
12% of the 100 and 83 controls were positive for
ANA antibodies7, 8. Moreover, the frequency of auto
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antibodies depends on the type of epilepsy since aCL
and ANA are more common in partial epilepsy9 and in
localisation-related epilepsy8. In a survey of children,
almost 30% of patients with epilepsy were positive
for at least one subtype of aCL11. In a study of 50
children and 20 healthy subjects a higher frequency of
anti phospholipid antibodies was found in the study
group (44%) compared with controls (10%)10. In these
couple of studies, too, the positivity of auto antibod-
ies were more frequent in symptomatic generalised
epilepsy (32 and 71%) than in generalised idiopathic
epilepsy (10 and 15%)10, 11. Our survey that included
a weak proportion of partial epilepsy could explain
why the frequency of aCL, ANA, 2GP1 antibodies
was the same among epileptic patients and controls.
The finding of a greater prevalence of ANA and
aCL in some forms of seizure disorder does not mean
that these auto antibodies really play a role in the
pathogenesis of epilepsy. First, too few convincing
data regarding brain ischemia in SLE and non-SLE
associated epilepsy have been published16. Unlike
Rasmussen encephalitis associated epilepsy where an-
tibodies to GluR3 have been demonstrated to promote
in vitro neuronal cell death and to lead to induced
seizures, antibodies directed to transmitter receptors
have never been demonstrated in patients with SLE
or epilepsy16. On the other hand, purified IgG con-
taining APA can depolarise synaptoneurosomes from
rat brainstem, suggesting this as a mechanism in cen-
tral nervous system manifestations17. Finally, efficacy
of intravenous immunoglobulins in the treatment of
some drug-refractory seizures could support the im-
munogenetic hypothesis for these epilepsies18. How-
ever, further studies are needed to exactly determine
what subsets of epilepsy could be immune-mediated.
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